Factor X inhibitors.
Factor X plays a central role in coagulation, being the point of convergence of the extrinsic and intrinsic pathways of blood clotting. It may also act as one of the links between the coagulation and inflammatory pathways. These findings suggest that factor X may represent an attractive target for a new antithrombotic drug. Indeed, a factor X inhibitor, fondaparinux, has already been approved for clinical use to prevent post-operative deep vein thrombosis. Factor X inhibitors are also being evaluated for use in the treatment of the acute coronary syndromes, pulmonary embolism and deep vein thrombosis. Oral factor X inhibitors are also being developed, which may be of use in the outpatient prevention and/or treatment of stroke and thromboembolism.
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK. g.y.h.lip@bham.ac.uk
Kiat Tsong
KT
Tan
Andrew
A
Makin
Gregory Y H
GY
Lip
D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005170:Factor X / Q000037:antagonists & inhibitors*; D065427:Factor Xa Inhibitors; D000077425:Fondaparinux; D006801:Humans; D011134:Polysaccharides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control; D020246:Venous Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; D005170:Factor X; D000077425:Fondaparinux